Sondelbay®
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
24/03/2022
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
24/03/2022
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.